ArticleBreast cancer research : BCR2008
Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'.
Article in Breast cancer research : BCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios as inflammatory markers in the assessment of glycemic status in diabetic patients of Asir region.Animal models and experimental medicine · 2025Article
- Review
- Article
- A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.Virchows Archiv : an international journal of pathology · 2015Article
- Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology?Journal of mammary gland biology and neoplasia · 2014Review
- Article
- Can tissue-based immune markers be used for studying the natural history of cancer?Annals of epidemiology · 2012Article
- Article
- Automation of immunohistochemical evaluation in breast cancer using image analysis.World journal of clinical oncology · 2011Article
- Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.Journal of the American Society for Mass Spectrometry · 2011Article
- Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.Nature reviews. Cancer · 2010Review
- Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.BMC cancer · 2010Article
- Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.Breast cancer research : BCR · 2008Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An urgent requirement exists for new prognostic and predictive assays in breast cancer. Despite the development of high-throughput technologies such as DNA microarrays, it would now appear that immunohistochemistry (IHC) may play an increasingly important role in the clinical management of breast cancer. In this editorial, the authors discuss the potential prognostic ability of a panel of IHC markers, and question whether this well-established assay technology may in fact allow for improved prognostic and predictive tests in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.